Pinnacle Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Pinnacle Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,783	Closed	-$2.22M	–	43
2024 Q3	$2.22M	Buy	+4,783	New	+$2.3M	2.66%	21
2024 Q2	–	Sell	-3,865	Closed	-$1.62M	–	53
2024 Q1	$1.62M	Buy	+3,865	New	+$1.63M	1.68%	31
2023 Q4	–	Sell	-4,494	Closed	-$1.56M	–	46
2023 Q3	$1.56M	Buy	4,494 +85	+2%	+$29.7K	1.9%	26
2023 Q2	$1.55M	Buy	+4,409	New	+$1.49M	1.57%	31

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pinnacle Wealth Management's VRTX Position: Q4 2024 in Review

Pinnacle Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 4,783 shares — an estimated $2.22M sold.

Pinnacle Wealth Management first reported a position in VRTX in Q2 2023 and held it in 4 quarters. The position peaked at $2.22M in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Pinnacle Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Pinnacle Wealth Management sold 4,783 Vertex Pharmaceuticals shares in Q4 2024, an estimated $2.22M.
Pinnacle Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 4 quarters.
Pinnacle Wealth Management's Vertex Pharmaceuticals position peaked at $2.22M in Q3 2024.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Pinnacle Wealth Management's 13F filing for Q4 2024, filed 18 Feb 2025.